Maze Therapeutics (MAZE) FCF Margin (2024 - 2026)
Maze Therapeutics (MAZE) posted FCF Margin of 196.03% for Q1 2026, down 1378.04% sequentially from 15.34% in Q4 2024.
Powered by 
Analysis
Maze Therapeutics (MAZE) FCF Margin (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported FCF Margin for 2 years, with the latest figure at 196.03% in Q1 2026.
- Quarterly FCF Margin changed N/A year-over-year to 196.03% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 610.62% (down 55973.0% YoY) and the FY2024 annual result came in at 498.71%, changed N/A from the prior year.
- FCF Margin fell to 196.03% in Q1 2026 per MAZE's latest filing, from 15.34% in the prior quarter.
- Over five years, FCF Margin peaked at 968.63% in Q2 2024 and troughed at 935.24% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Maze Therapeutics | 1.55 Bn | 1.55 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -196.03% |
| Sep 30, 2024 | -932.32% |
| Jun 30, 2024 | 87.81% |